Milos Opravil
Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy
Schmid P, Weber R, Opravil M, Vernazza P, Mullhaupt B, Jochum W, Rauch A, Huber M, Bregenzer A, Swiss HIV Cohort Study. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PloS one 2015; 10:e0138838.
Sep 29, 2015Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy
Sep 29, 2015PloS one 2015; 10:e0138838
Schmid Patrick, Weber Rainer, Opravil Milos, Vernazza Pietro, Mullhaupt Beat, Jochum Wolfram, Rauch Andri, Huber Milo, Bregenzer Andrea, Swiss HIV Cohort Study
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid
Cusini A, Günthard H, Opravil M, Gutmann C, Zenger F, Klimkait T, Cavassini M, Gaudenz R, Hirschel B, Widmer N, Rohrbach J, Fux C, Ledergerber B, Decosterd L, Yerly S, Vernazza P, Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 2013; 62:28-35.
Jan 1, 2013Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid
Jan 1, 2013J Acquir Immune Defic Syndr 2013; 62:28-35
Cusini Alexia, Günthard Huldyrich F, Opravil Milos, Gutmann Christine, Zenger Franziska, Klimkait Thomas, Cavassini Matthias, Gaudenz Roman, Hirschel Bernhard, Widmer Nicolas, Rohrbach Janine, Fux Christoph A, Ledergerber Bruno, Decosterd Laurent A, Yerly Sabine, Vernazza Pietro, Swiss HIV Cohort Study
Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007
Ballif M, Weber R, Opravil M, Rickenbach M, Furrer H, Hirschel B, Schmid P, Bernasconi E, Cavassini M, Battegay M, Ledergerber B, Swiss HIV Cohort Study. Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PloS one 2009; 4:e8275.
Jan 1, 2009Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007
Jan 1, 2009PloS one 2009; 4:e8275
Ballif Marie, Weber Rainer, Opravil Milos, Rickenbach Martin, Furrer Hansjakob, Hirschel Bernard, Schmid Patrick, Bernasconi Enos, Cavassini Matthias, Battegay Manuel, Ledergerber Bruno, Swiss HIV Cohort Study
CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
Khanna N, Kaufmann G, Battegay M, Hirschel B, Weber R, Bernasconi E, Vernazza P, Cavassini M, Furrer H, Opravil M, Swiss HIV Cohort Study. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 47:1093-101.
Oct 15, 2008CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
Oct 15, 2008Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 47:1093-101
Khanna Nina, Kaufmann Gilbert R, Battegay Manuel, Hirschel Bernard, Weber Rainer, Bernasconi Enos, Vernazza Pietro, Cavassini Matthias, Furrer Hansjakob, Opravil Milos, Swiss HIV Cohort Study
Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study
Fux C, Furrer H, Elzi L, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Hirschel B, Bucher H, Simcock M, Rauch A, Swiss HIV Cohort Study. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antiviral therapy 2008; 13:1077-82.
Jan 1, 2008Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study
Jan 1, 2008Antiviral therapy 2008; 13:1077-82
Fux Christoph A, Furrer Hansjakob, Elzi Luigia, Bernasconi Enos, Cavassini Matthias, Vernazza Pietro, Opravil Milos, Hirschel Bernard, Bucher Heiner C, Simcock Mathew, Rauch Andri, Swiss HIV Cohort Study
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
Wolbers M, Bucher H, Günthard H, Yerly S, Battegay M, Bernasconi E, Vernazza P, Cavassini M, Furrer H, Hirschel B, von Wyl V, Opravil M, Swiss HIV Cohort Study. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS (London, England) 2007; 21:2201-7.
Oct 18, 2007Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
Oct 18, 2007AIDS (London, England) 2007; 21:2201-7
Wolbers Marcel, Bucher Heiner C, Günthard Huldrych, Yerly Sabine, Battegay Manuel, Bernasconi Enos, Vernazza Pietro, Cavassini Matthias, Furrer Hansjakob, Hirschel Bernard, von Wyl Viktor, Opravil Milos, Swiss HIV Cohort Study
Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification
Keiser O, Furrer H, Telenti A, Rickenbach M, Vernazza P, Bernasconi E, Hirschel B, Hirsch H, Opravil M, Fellay J, Swiss HIV Cohort Study. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antiviral therapy 2007; 12:1157-64.
Jan 1, 2007Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification
Jan 1, 2007Antiviral therapy 2007; 12:1157-64
Keiser Olivia, Furrer Hansjakob, Telenti Amalio, Rickenbach Martin, Vernazza Pietro, Bernasconi Enos, Hirschel Bernard, Hirsch Hans H, Opravil Milos, Fellay Jacques, Swiss HIV Cohort Study
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study
Fux C, Furrer H, Elzi L, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Hirschel B, Bucher H, Wolbers M, Simcock M, Swiss HIV Cohort Study. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral therapy 2007; 12:1165-73.
Jan 1, 2007Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study
Jan 1, 2007Antiviral therapy 2007; 12:1165-73
Fux Christoph A, Furrer Hansjakob, Elzi Luigia, Bernasconi Enos, Cavassini Matthias, Vernazza Pietro, Opravil Milos, Hirschel Bernard, Bucher Heiner C, Wolbers Marcel, Simcock Mathew, Swiss HIV Cohort Study
Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
Zinkernagel A, Weber R, Schmid P, Bernasconi E, Opravil M, Tarr P, Hirschel B, Battegay M, Furrer H, Rickenbach M, Ledergerber B, von Wyl V, Swiss HIV Cohort Study. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy 2006; 11:131-42.
Jan 1, 2006Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
Jan 1, 2006Antiviral therapy 2006; 11:131-42
Zinkernagel Annelies S, Weber Rainer, Schmid Patrick, Bernasconi Enos, Opravil Milos, Tarr Philip E, Hirschel Bernard, Battegay Manuel, Furrer Hansjakob, Rickenbach Martin, Ledergerber Bruno, von Wyl Viktor, Swiss HIV Cohort Study
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Perrin L, Ledergerber B, Furrer H, Swiss HIV Cohort Study. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:361-72.
Aug 1, 2005Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
Aug 1, 2005Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:361-72
Kaufmann Gilbert R, Battegay Manuel, Hirschel Bernard, Rickenbach Martin, Bernasconi Enos, Cavassini Matthias, Vernazza Pietro, Opravil Milos, Perrin Luc, Ledergerber Bruno, Furrer Hansjakob, Swiss HIV Cohort Study
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
Opravil M, Perrin L, Ledergerber B, Vernazza P, Blasko M, Bernasconi E, Calmy A, Furrer H, Chave J, Baumann D, Swiss HIV Cohort Study. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS (London, England) 2004; 18:2213-5.
Nov 5, 2004Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
Nov 5, 2004AIDS (London, England) 2004; 18:2213-5
Opravil Milos, Perrin Luc, Ledergerber Bruno, Vernazza Pietro, Blasko Monika, Bernasconi Enos, Calmy Alexandra, Furrer Hansjakob, Chave Jean-Philippe, Baumann Doris, Swiss HIV Cohort Study
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
Kaufmann G, Battegay M, Egger M, Rickenbach M, Bernasconi E, Vernazza P, Ledergerber B, Hirschel B, Telenti A, Furrer H, Opravil M, Pantaleo G, Perrin L, Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Archives of internal medicine 2003; 163:2187-95.
Oct 13, 2003CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
Oct 13, 2003Archives of internal medicine 2003; 163:2187-95
Kaufmann Gilbert R, Battegay Manuel, Egger Matthias, Rickenbach Martin, Bernasconi Enos, Vernazza Pietro, Ledergerber Bruno, Hirschel Bernard, Telenti Amalio, Furrer Hansjakob, Opravil Milos, Pantaleo Guiseppe, Perrin Luc, Swiss HIV Cohort Study Group
Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study
Bernasconi E, Telenti A, Rickenbach M, Weber R, Opravil M, Chave J, Boggian K, Hirschel B, Haensel A, Furrer H, Flepp M, Junghans C, Boubaker K, Swiss HIV Cohort Study. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31:50-5.
Sep 1, 2002Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study
Sep 1, 2002J Acquir Immune Defic Syndr 2002; 31:50-5
Bernasconi Enos, Telenti Amalio, Rickenbach Martin, Weber Rainer, Opravil Milos, Chave Jean-Philippe, Boggian Katia, Hirschel Bernard, Haensel Alexander, Furrer Hans-Jakob, Flepp Markus, Junghans Cornelia, Boubaker Karim, Swiss HIV Cohort Study
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
Opravil M, Perrin L, Weber R, Howe C, Günthard H, Ledergerber B, Battegay M, Bernasconi E, Vernazza P, Fischer M, Bisset L, Yerly S, Chave J, Furrer H, Lazzarin A, Hirschel B, Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. The Journal of infectious diseases 2002; 185:1251-60.
May 1, 2002A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
May 1, 2002The Journal of infectious diseases 2002; 185:1251-60
Opravil Milos, Perrin Luc, Weber Rainer, Howe Colin, Günthard Huldrych, Ledergerber Bruno, Battegay Manuel, Bernasconi Enos, Vernazza Pietro, Fischer Marek, Bisset Leslie R, Yerly Sabine, Chave Jean-Philippe, Furrer Hansjakob, Lazzarin Adriano, Hirschel Bernard, Swiss HIV Cohort Study
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
Fellay J, Telenti A, Eap C, Vernazza P, Schinkel A, Ruiz L, Retelska D, Pantaleo G, Opravil M, Furrer H, Decosterd L, Chave J, Buclin T, Back D, Meaden E, Marzolini C, Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-6.
Jan 5, 2002Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
Jan 5, 2002Lancet 2002; 359:30-6
Fellay Jacques, Telenti Amalio, Eap Chin B, Vernazza Pietro, Schinkel Alfred H, Ruiz Lidia, Retelska Dorota, Pantaleo Giuseppe, Opravil Milos, Furrer Hansjakob, Decosterd Laurent A, Chave Jean Philippe, Buclin Thierry, Back David J, Meaden Emma R, Marzolini Catia, Swiss HIV Cohort Study